X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-11-22 | ADMA | Adma Biologics, Inc. | Tade Brad L. | CFO, Treasurer | S - Sale | $21.15 | -15,000 | 199,433 | -7% | -$317,250 | ||||||
2024-11-22 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale | $21.10 | -48,967 | 3,713,390 | -1% | -$1,033,204 | ||||||
| M | 2024-11-20 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | 10% | P - Purchase | $3.95 | +11,008 | 301,901 | +4% | +$43,507 | |||||
| D | 2024-11-21 | RGEN | Repligen Corp | Hunt Anthony | Dir | S - Sale+OE | $139.67 | -24,246 | 139,840 | -15% | -$3,386,439 | |||||
2024-11-20 | IMVT | Immunovant, Inc. | Levine Mark S. | GC | S - Sale | $25.45 | -3,650 | 319,228 | -1% | -$92,893 | ||||||
2024-11-20 | IMVT | Immunovant, Inc. | Macias William L. | Chief Medical Officer | S - Sale | $25.45 | -3,353 | 361,791 | -1% | -$85,334 | ||||||
2024-11-20 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $25.45 | -4,174 | 331,169 | -1% | -$106,228 | ||||||
2024-11-20 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $25.45 | -16,692 | 978,097 | -2% | -$424,811 | ||||||
| M | 2024-11-19 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Dir | P - Purchase | $14.21 | +107,186 | 139,686 | +330% | +$1,523,620 | |||||
2024-11-21 | LCTX | Lineage Cell Therapeutics, Inc. | Culley Brian M | Pres, CEO | P - Purchase | $0.60 | +40,000 | 194,842 | +26% | +$24,000 | ||||||
2024-11-21 | DTIL | Precision Biosciences Inc | Kelly John Alexander | CFO | P - Purchase | $6.76 | +3,000 | 38,073 | +9% | +$20,280 | ||||||
2024-11-20 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.20 | +85,000 | 1,637,968 | +5% | +$16,915 | ||||||
2024-11-20 | AIM | Aim Immunotech Inc. | Appelrouth Stewart | Dir | P - Purchase | $0.19 | +81,953 | 321,752 | +34% | +$15,817 | ||||||
2024-11-19 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | P - Purchase | $4.44 | +1,797 | 3,633,136 | 0% | +$7,979 | ||||||
2024-11-19 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | P - Purchase | $4.44 | +1,797 | 3,633,136 | 0% | +$7,979 | ||||||
2024-11-18 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $10.78 | -7,246 | 109,885 | -6% | -$78,112 | ||||||
2024-11-18 | REPL | Replimune Group, Inc. | Sarchi Christopher | Chief Commercial Officer | S - Sale | $10.78 | -5,207 | 87,045 | -6% | -$56,131 | ||||||
| M | 2024-11-18 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | S - Sale | $4.40 | -1,500,000 | 3,631,339 | -29% | -$6,606,799 | |||||
| M | 2024-11-18 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | S - Sale | $4.40 | -1,500,000 | 3,631,339 | -29% | -$6,606,799 | |||||
| M | 2024-11-18 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | 10% | P - Purchase | $2.66 | +22,289 | 290,893 | +8% | +$59,195 | |||||
2024-11-18 | ATRA | Atara Biotherapeutics, Inc. | Henrich Jill | EVP, Chief Regulatory Officer | S - Sale | $11.20 | -1,000 | 19,378 | -5% | -$11,198 | ||||||
2024-11-18 | ATRA | Atara Biotherapeutics, Inc. | Hyllengren Eric J | EVP, CFO, COO | S - Sale | $11.20 | -1,364 | 23,392 | -6% | -$15,274 | ||||||
2024-11-18 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $11.20 | -1,664 | 77,454 | -2% | -$18,633 | ||||||
2024-11-19 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.55 | -554 | 68,506 | -1% | -$304 | ||||||
2024-11-19 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.55 | -3,186 | 17,815,660 | 0% | -$1,748 | ||||||
2024-11-19 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.55 | -432 | 500,298 | 0% | -$237 | ||||||
2024-11-19 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.55 | -8,706 | 723,363 | -1% | -$4,775 | ||||||
2024-09-25 | CERO | Cero Therapeutics Holdings, Inc. | Sloan Stuart M | 10% | S - Sale | $0.10 | -532,486 | 21,067,956 | -2% | -$55,538 | ||||||
2024-11-20 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.18 | +60,110 | 1,552,968 | +4% | +$11,000 | ||||||
2024-11-18 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $34.36 | -41,588 | 322,852 | -11% | -$1,428,822 | ||||||
2024-11-19 | ITOS | Iteos Therapeutics, Inc. | Gall Matthew | CFO | P - Purchase | $7.73 | +5,000 | 65,429 | +8% | +$38,635 | ||||||
| D | 2024-11-15 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale+OE | $88.87 | -1,761 | 3,000 | -37% | -$156,508 | |||||
2024-11-18 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $4.98 | -248 | 154,330 | 0% | -$1,235 | ||||||
2024-11-15 | IZTC | Invizyne Technologies Inc | Heltzen Michael | CEO | P - Purchase | $11.10 | +1,984 | 1,984 | New | +$22,022 | ||||||
| D | 2024-11-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $85.81 | -8,000 | 109,491 | -7% | -$686,518 | |||||
2024-11-15 | XFOR | X4 Pharmaceuticals, Inc | Ragan Paula | Pres, CEO | S - Sale | $0.39 | -31,897 | 993,919 | -3% | -$12,583 | ||||||
2024-11-15 | TCRX | Tscan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $4.34 | +947 | 5,225,547 | 0% | +$4,114 | ||||||
2024-11-15 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $55.13 | -2,554 | 43,080 | -6% | -$140,811 | ||||||
2024-11-15 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.87 | +1,350 | 105,331 | +1% | +$2,525 | ||||||
2024-11-18 | AURA | Aura Biosciences, Inc. | Hopkins Janet Jill | Chief Medical Officer | S - Sale | $9.36 | -11,822 | 151,693 | -7% | -$110,663 | ||||||
2024-11-18 | TNYA | Tenaya Therapeutics, Inc. | Saito Chihiro | SVP, Accounting, Fin. Ops. | S - Sale | $2.12 | -2,258 | 60,983 | -4% | -$4,787 | ||||||
| DM | 2024-11-13 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $7.55 | -40,000 | 762,656 | -5% | -$301,800 | |||||
| D | 2024-11-13 | ECL | Ecolab Inc. | Higgins Arthur J | Dir | S - Sale+OE | $249.81 | -2,000 | 26,201 | -7% | -$499,622 | |||||
2024-11-13 | ACOG | Alpha Cognition Inc. | McFadden Michael E. | CEO | P - Purchase | $5.75 | +2,608 | 14,142 | +23% | +$14,996 | ||||||
2024-11-13 | ACOG | Alpha Cognition Inc. | Mertz Leonard Powell | Dir | P - Purchase | $5.75 | +8,695 | 232,220 | +4% | +$49,996 | ||||||
2024-11-13 | ACOG | Alpha Cognition Inc. | Havens John Prentiss | Dir | P - Purchase | $5.75 | +4,347 | 285,587 | +2% | +$24,995 | ||||||
| D | 2024-11-13 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $58.65 | -16,666 | 264,408 | -6% | -$977,509 | |||||
| D | 2024-11-13 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $55.54 | -7,000 | 11,900 | -37% | -$388,780 | |||||
| DM | 2024-11-13 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $54.75 | -35,000 | 220,937 | -14% | -$1,916,250 | |||||
| A | 2024-11-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $44.61 | -1,811 | 92,670 | -2% | -$80,780 | |||||
| A | 2024-11-06 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $44.61 | -4,160 | 89,237 | -4% | -$185,557 | |||||
| AD | 2024-11-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $44.61 | -14,334 | 589,552 | -2% | -$639,368 | |||||
| A | 2024-11-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $44.61 | -1,448 | 45,620 | -3% | -$64,588 | |||||
| A | 2024-11-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $44.61 | -5,519 | 115,494 | -5% | -$246,175 | |||||
| A | 2024-11-06 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $44.61 | -6,239 | 231,401 | -3% | -$278,291 | |||||
2024-10-10 | CERO | Cero Therapeutics Holdings, Inc. | Yk Bioventures Opportunities Gp I, LLC | 10% | S - Sale | $0.10 | -3,250,000 | 22,620,783 | -13% | -$325,000 | ||||||
2024-11-12 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $7.64 | -11,447 | 7,066,113 | 0% | -$87,457 | ||||||
| DM | 2024-11-12 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $7.65 | -30,000 | 1,499,631 | -2% | -$229,505 | |||||
| D | 2024-11-12 | IOVA | Iovance Biotherapeutics, Inc. | Maynard Ryan D | Dir | S - Sale+OE | $10.06 | -50,000 | 7,500 | -87% | -$503,000 | |||||
| D | 2024-11-12 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $106.33 | -1,500 | 0 | -100% | -$159,495 | |||||
| D | 2024-11-11 | TWST | Twist Bioscience Corp | Chess Robert | Dir | S - Sale+OE | $47.26 | -3,600 | 64,169 | -5% | -$170,139 | |||||
2024-11-11 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale | $55.62 | -30,000 | 282,162 | -10% | -$1,668,678 | ||||||
| D | 2024-11-11 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale+OE | $7.82 | -2,500 | 120,695 | -2% | -$19,557 | |||||
2024-11-11 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $48.00 | -1,507 | 91,163 | -2% | -$72,333 | ||||||
2024-11-11 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $48.00 | -10,340 | 221,061 | -4% | -$496,299 | ||||||
2024-11-11 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $48.00 | -1,347 | 114,147 | -1% | -$64,653 | ||||||
| D | 2024-11-11 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $48.00 | -7,968 | 581,584 | -1% | -$382,448 | |||||
| D | 2024-11-11 | SRRK | Scholar Rock Holding Corp | Marantz Jing L. | Chief Medical Officer | S - Sale+OE | $30.00 | -2,105 | 72,855 | -3% | -$63,158 | |||||
| D | 2024-11-11 | DNLI | Denali Therapeutics Inc. | Schenkein David P | Dir | S - Sale+OE | $32.51 | -59,441 | 66,684 | -47% | -$1,932,665 | |||||
| DM | 2024-11-11 | VCEL | Vericel Corp | Zerbe Robert L Md | Dir | S - Sale+OE | $56.25 | -5,000 | 26,595 | -16% | -$281,250 | |||||
| D | 2024-11-08 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale+OE | $100.55 | -12,354 | 1,761 | -88% | -$1,242,170 | |||||
| DM | 2024-11-07 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $103.90 | -57,479 | 0 | -100% | -$5,971,809 | |||||
| D | 2024-11-07 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COFO, Secretary | S - Sale+OE | $29.91 | -15,558 | 701,815 | -2% | -$465,286 | |||||
2024-11-07 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $30.00 | -1,020 | 111,056 | -1% | -$30,600 | ||||||
| D | 2024-11-11 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $46.10 | -277 | 1,599,297 | 0% | -$12,771 | |||||
| D | 2024-11-07 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $103.89 | -2,366 | 603,409 | 0% | -$245,796 | |||||
2024-11-06 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $59.12 | -6,665 | 267,463 | -2% | -$394,041 | ||||||
2024-11-06 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $59.22 | -15,000 | 1,339,487 | -1% | -$888,320 | ||||||
| D | 2024-11-06 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale+OE | $60.00 | -6,000 | 45,634 | -12% | -$360,000 | |||||
2024-11-06 | BEAM | Beam Therapeutics Inc. | Ciaramella Giuseppe | Pres | S - Sale | $26.36 | -51,110 | 109,150 | -32% | -$1,347,050 | ||||||
| D | 2024-11-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $44.61 | -14,334 | 589,552 | -2% | -$639,368 | |||||
2024-11-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $44.61 | -1,448 | 45,620 | -3% | -$64,588 | ||||||
2024-11-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $44.61 | -5,519 | 115,494 | -5% | -$246,175 | ||||||
2024-11-06 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $44.61 | -4,160 | 89,237 | -4% | -$185,557 | ||||||
2024-11-06 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $44.61 | -6,239 | 231,401 | -3% | -$278,291 | ||||||
2024-11-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $44.61 | -1,811 | 92,670 | -2% | -$80,780 | ||||||
| D | 2024-11-05 | EXEL | Exelixis, Inc. | Aftab Dana | CSO, EVP Disc, Trans Research | S - Sale+OE | $35.00 | -96,986 | 504,780 | -16% | -$3,394,510 | |||||
2024-11-06 | VIR | Vir Biotechnology, Inc. | De Verneuil Vanina | EVP, GC | S - Sale | $10.11 | -4,397 | 56,973 | -7% | -$44,454 | ||||||
2024-11-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $15.64 | -8,000 | 107,942 | -7% | -$125,120 | ||||||
2024-11-06 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $91.28 | -5,000 | 73,127 | -6% | -$456,400 | ||||||
| D | 2024-11-06 | GILD | Gilead Sciences, Inc. | Parsey Merdad | Chief Medical Officer | S - Sale+OE | $91.50 | -25,590 | 99,599 | -20% | -$2,341,485 | |||||
2024-11-04 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $41.56 | -1,057 | 121,013 | -1% | -$43,933 | ||||||
2024-11-04 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $41.56 | -659 | 94,481 | -1% | -$27,391 | ||||||
| D | 2024-11-04 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $41.56 | -4,841 | 603,886 | -1% | -$201,211 | |||||
2024-11-04 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $41.56 | -2,681 | 237,640 | -1% | -$111,433 | ||||||
2024-11-04 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $41.56 | -156 | 47,068 | 0% | -$6,484 | ||||||
| D | 2024-11-04 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $7.58 | -333 | 6,456 | -5% | -$2,523 | |||||
| D | 2024-11-04 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $7.58 | -1,322 | 31,610 | -4% | -$10,015 | |||||
| D | 2024-11-05 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $106.36 | -5,000 | 28,623 | -15% | -$531,803 | |||||
2024-11-05 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.86 | -10,609 | 732,069 | -1% | -$9,176 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |